Advertisement


Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy

2025 ASCO Annual Meeting

Advertisement

Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
As you may know, Lynch syndrome is a genetic predisposition, meaning it's defined by a germline mutation in an MMR protein. The different proteins affected are MLH1, MSH2, MSH6, and PMS2. Patients affected by Lynch syndrome actually develop tumors in gastrointestinal sites, endometrial sites, urological, or pancreas-biliary. The question we asked in that study is, could the different variants affected actually impact the response to immune checkpoint blockade? Because right now, immune checkpoint blockades are the reference treatment in metastatic cancers affecting the Lynch syndrome patients. What we observed is that yes, but no. I'm going to develop that. First part is yes, because when we take the whole cohort, we have a retrospectively collected cohort at Memorial Sloan Kettering throughout 10 years, including Lynch syndrome patients with advanced tumors treated by at least one dose of immune checkpoint blockade, and we considered only the first tumor treated by immune checkpoint blockade. Our primary outcome was overall survival. Secondary outcomes were progression-free survival and radiological response rates. Of course, we were also interested in tumor mutational burden and MSI score. When we looked at our primary outcome, which was overall survival, indeed, PMS2 carriers were doing less well than the others. They had a median overall survival of about 21 months, while the other ones were plateauing with about 9 to 10 years of overall survival in advanced tumors. When we looked at median progression-free survival, it was pretty much the same. PMS2 patients had significantly shortened median PFS of 7.2 months, while the others were far longer. Again, with the radiological response rates, we could see a gradient. Only 9% of the PMS2 carriers experienced complete response in that setting, while MSH6 carriers were about 22% to experience that, and the other germline carriers were above 40% of complete response rates, which is amazing in the advanced tumor setting. But we actually saw in our cohort that many of the PMS2 variant carriers actually displayed MSS tumors. They were not MSI-high for 63% of them. So we chose to select only the MSI-high tumors, and then all the effects on the PMS2 carriers were erased. They had the same overall survival, they had the same median progression-free survival, and they experienced about 30% complete response rates. So this means that tomorrow, for PMS2 carrier patients diagnosed with an advanced tumor, we really need to analyze its tumor thoroughly with MSI score and MMR staining to make sure that the tumor is MMR-D/MSI-high. If this tumor is confirmed MSI-high, he has an outstanding prognosis, as good as the other patients. If it's MMR-P/MS-stable tumors, he's not going to respond to immune checkpoint blockade and we should have him under standard-of-care treatment. So that's a small question maybe, but so important for patients that are affected by Lynch syndrome.

Related Videos

Leukemia

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy. 

 

Colorectal Cancer

Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial

Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encorafenib, cetuximab, and mFOLFOX6 in BRAF V600E–mutant metastatic colorectal cancer (LBA3500). 

Breast Cancer

Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508). 

Genomics/Genetics

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).  

Advertisement

Advertisement




Advertisement